<bill session="107" type="h" number="5272" updated="2013-07-14T18:58:45-04:00">
  <state datetime="2002-07-26">REFERRED</state>
  <status>
    <introduced datetime="2002-07-26"/>
  </status>
  <introduced datetime="2002-07-26"/>
  <titles>
    <title as="introduced" type="short">Prescription Drug Fair Competition Act of 2002</title>
    <title as="introduced" type="official">To amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals.</title>
  </titles>
  <sponsor id="400050"/>
  <cosponsors>
    <cosponsor id="400001" joined="2002-10-01"/>
    <cosponsor id="400011" joined="2002-09-24"/>
    <cosponsor id="400526" joined="2002-09-24"/>
    <cosponsor id="400553" joined="2002-09-24"/>
    <cosponsor id="400133" joined="2002-09-26"/>
    <cosponsor id="400140" joined="2002-09-24"/>
    <cosponsor id="400216" joined="2002-09-24"/>
    <cosponsor id="400246" joined="2002-09-10"/>
    <cosponsor id="400251" joined="2002-09-24"/>
    <cosponsor id="400258" joined="2002-09-26"/>
    <cosponsor id="400259" joined="2002-09-24"/>
    <cosponsor id="400262" joined="2002-09-10"/>
    <cosponsor id="400301" joined="2002-09-17"/>
    <cosponsor id="400312" joined="2002-09-26"/>
    <cosponsor id="400528" joined="2002-09-11"/>
    <cosponsor id="400345" joined="2002-09-17"/>
    <cosponsor id="400361" joined="2002-09-24"/>
    <cosponsor id="400509" joined="2002-09-24"/>
    <cosponsor id="400425" joined="2002-07-26"/>
    <cosponsor id="400430" joined="2002-09-17"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2002-07-26">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2002-07-29">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Access to health care"/>
    <term name="Actions and defenses"/>
    <term name="Administrative procedure"/>
    <term name="Commerce"/>
    <term name="Competition"/>
    <term name="Confidential communications"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Damages"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Generic drugs"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Government publicity"/>
    <term name="Injunctions"/>
    <term name="Intellectual property"/>
    <term name="Labeling"/>
    <term name="Law"/>
    <term name="Limitation of actions"/>
    <term name="Marketing"/>
    <term name="Patent infringement"/>
    <term name="Patents"/>
    <term name="Prescription pricing"/>
    <term name="Restrictive trade practices"/>
    <term name="Trade secrets"/>
  </subjects>
  <amendments/>
  <summary>7/26/2002--Introduced.
Prescription Drug Fair Competition Act of 2002 - Amends the Federal Food, Drug, and Cosmetic Act to revise provisions concerning the timing of generic drug availability.Requires applicants (pharmaceutical companies) to register their patents with the Food and Drug Administration (FDA) within 30 days of approval (or issuance for subsequently issued patents).Makes failure to timely register a bar to civil actions for patent infringement.Requires applications for new drugs (NDA) or abbreviated new drug applications (ANDA) which rely upon investigations not conducted by or for the applicant and which concern a patent that claims both the drug and a method of use or more than one method of use to include a certification on a claim-by-claim basis that the patent is invalid or will not be infringed (known as a Paragraph IV filing/certification) by the new drug's (generic) manufacture and a statement regarding the method(s) of use claim.Prohibits (for subsequently issued patents) an extension of the 30 month stay of FDA approval for any new drug where an ANDA or NDA contains a Paragraph IV filing/certification and the patent holder indicates an intention to bring a patent infringement suit against the new (generic) drug's manufacturer.Makes failure to timely file a civil action for infringement a bar to later action.Requires the first generic applicant with a Paragraph IV filing to forfeit the 180 day marketing exclusivity period to a subsequent generic applicant if the first generic applicant engages in certain behaviors which delay or prevent the marketing of the generic drug.Revises notice requirements for Paragraph IV filings to include and protect certain proposed formulation, composition, or method of use information.Excludes an applicants's ability to pay damages from a court's consideration of whether or not to provide injunctive relief before the expiration of the 30 month stay of approval period.</summary>
</bill>
